Fulcrum Therapeutics, Inc. (FULC)
Automate Your Wheel Strategy on FULC
With Tiblio's Option Bot, you can configure your own wheel strategy including FULC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol FULC
- Rev/Share 0.0
- Book/Share 3.1689
- PB 3.1967
- Debt/Equity 0.0353
- CurrentRatio 17.698
- ROIC -0.3965
- MktCap 548148259.0
- FreeCF/Share -0.9651
- PFCF -9.0732
- PE -8.9168
- Debt/Assets 0.0326
- DivYield 0
- ROE -0.3217
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | FULC | Truist | -- | Buy | -- | -- | Nov. 24, 2025 |
| Upgrade | FULC | H.C. Wainwright | Neutral | Buy | $4 | $12 | July 29, 2025 |
| Upgrade | FULC | Leerink Partners | Market Perform | Outperform | -- | $12 | May 23, 2025 |
| Upgrade | FULC | Cantor Fitzgerald | Neutral | Overweight | -- | $10 | May 15, 2025 |
| Downgrade | FULC | H.C. Wainwright | Buy | Neutral | $17 | $4 | Sept. 13, 2024 |
| Downgrade | FULC | BofA Securities | Neutral | Underperform | $10 | $2 | Sept. 12, 2024 |
| Downgrade | FULC | Leerink Partners | Outperform | Market Perform | -- | $4 | Sept. 12, 2024 |
| Downgrade | FULC | Cantor Fitzgerald | Overweight | Neutral | -- | -- | Sept. 12, 2024 |
| Downgrade | FULC | RBC Capital Mkts | Outperform | Sector Perform | $15 | $4 | Sept. 12, 2024 |
| Downgrade | FULC | Stifel | Buy | Hold | -- | -- | Sept. 12, 2024 |
News
Wall Street Analysts Think Fulcrum Therapeutics (FULC) Could Surge 58.47%: Read This Before Placing a Bet
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 58.5% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Fulcrum Therapeutics, Inc. (FULC) Q3 2025 Earnings Call Transcript
Published: October 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Fulcrum Therapeutics, Inc. ( FULC ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Alexander Sapir - CEO, President & Director Alan Musso - Chief Financial Officer Iain Fraser - Senior Vice President of Early Development Conference Call Participants Kristen Kluska - Cantor Fitzgerald & Co., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Corinne Jenkins - Goldman Sachs Group, Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Matthew Biegler - Oppenheimer & Co. Inc., Research Division Andres Maldonado - H.C. Wainwright & Co, LLC, Research Division Luca Issi - …
Read More
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
Published: October 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
― Announced encouraging results in July 2025 from the 12 mg dose cohort of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Enrollment complete in the 20 mg dose cohort (n=12) of the PIONEER trial; on track to provide data from the 20 mg dose cohort by year-end ― ― Ended Q3 2025 with $200.6 million in cash, cash equivalents, and marketable securities; cash runway into 2028 ― CAMBRIDGE, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the …
Read More
Fulcrum Metal shares jump as tailings project advances
Published: September 17, 2025 by: Proactive Investors
Sentiment: Positive
Fulcrum Metals Plc (LSE:FMET) shares soared in Wednesday's trade after announcing the start of its Phase Three optimisation work at the Teck-Hughes tailings project in Kirkland Lake, Ontario. The programme with Extrakt Process Solutions aims to refine cyanide-free leaching technology and recovery methods for gold and silver.
Read More
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2025
Published: May 01, 2025 by: GlobeNewsWire
Sentiment: Neutral
― Enrollment complete in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD); initiated the 20 mg dose cohort ―
Read More
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2024
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
― On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025 and the 20 mg dose cohort by the end of 2025 ―
Read More
About Fulcrum Therapeutics, Inc. (FULC)
- IPO Date 2019-07-18
- Website https://www.fulcrumtx.com
- Industry Biotechnology
- CEO Alexander C. Sapir
- Employees 45